Skip to content

Global Market

This Speculative Biotech’s Treatment Candidate For Head And Neck Cancer Gives It Massive Upside Potential

With the global market for head and neck cancer expected to reach $4.5 billion by 2027, the clinical-stage immuno-oncology company highlighted in today’s article – which has entered into a clinical trial collaboration with Merck to treat patients with head and neck squamous cell carcinoma with its lead product candidate – has massive upside potential. For more on this company…